Ionis Pharmaceuticals (IONS) is a biotechnology pharmaceutical company with commercial revenue, a large pipeline of RNA-based therapies, and an extensive partner network.
Ionis licensed a therapy for Huntington's disease to Roche (RHHBY). On January 28, Ionis and Roche announced the first patient had been dosed in a Phase 3 trial. Ionis thereby earned a $35 million milestone payment.
This confirms my thesis that Ionis is on a path highly likely to bring alpha returns to investors. This article will provide some details that support this view, which was developed in my prior articles